Scribe Therapeutics (SCRE) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on in vivo CRISPR technologies for common diseases, especially cardiovascular and metabolic conditions.

• Lead program STX-1150 targets LDL-C via epigenetic silencing of PCSK9; additional programs target Lp(a) and triglycerides.

• Proprietary CRISPR by Design approach leverages AI, machine learning, and parallel validation to engineer therapies.

• Strategic collaborations with Sanofi and Lilly in rare genetic and neurological diseases; pipeline expansion planned.

• Founded by leaders in CRISPR, including Nobel Laureate Dr. Jennifer Doudna; strong IP portfolio based on CasX enzyme.

Financial performance and metrics

• Collaboration revenue: $51.2M in 2025, $27.4M in 2024; $2.2M in Q1 2026.

• Net loss: $21.8M in 2025, $47.8M in 2024; $17.4M loss in Q1 2026.

• Accumulated deficit: $175.1M as of March 31, 2026.

• Cash, cash equivalents, and investments: $49.7M as of March 31, 2026.

• Substantial doubt about ability to continue as a going concern; additional capital needed beyond IPO proceeds.

Use of proceeds and capital allocation

• Net proceeds to fund clinical development of STX-1150, advance STX-1200 and STX-1400, invest in pipeline and technology, and for working capital.

• Proceeds may also be used for in-licensing, acquisitions, or investments in complementary technologies.

• Existing cash plus IPO proceeds expected to fund operations through a defined period, but not through regulatory approval of any program.